2ⁿᵈ Edition of the Cancer R&D World Conference 2026

Scientific Sessions

Cancer Prevention and Early Detection Strategies

Effective cancer control represents a continuum from prevention through early detection to treatment. In fact, prevention and early detection offer the most powerful means for reducing the global burden of cancer. The identification and management of at-risk populations are being revolutionized by advances in molecular screening, genetic testing, and lifestyle-based interventions. Vaccination programs against oncogenic viruses enhance public health awareness and integrate AI-driven screening technologies, thus improving the precision and accessibility of early diagnosis. It is saving lives because cancers are being identified at their earliest, most treatable stages, providing for optimized treatment outcomes.

This session, at the Cancer Research and Development Conference 2026, will cover recent innovations in cancer prevention, risk assessment, and early detection. It will detail how precision screening, biomarker-based diagnostics, and population health initiatives will drive a decrease in cancer burden. Join us to explore the future of proactive oncology where prevention, early intervention, and technology converge to shape a healthier, cancer-free generation.

Related Sessions

Current Landscape and Future Directions of Oncology Research
Oncogenic Signaling Pathways and Therapeutic Targets
Emerging Biomarkers for Cancer Detection and Prognosis
Cancer Prevention and Early Detection Strategies
Immuno-Oncology and Cell-Based Therapies
Innovations in Immuno-Oncology
Cytokine Modulation and Immune Adjuvants in Cancer Immunotherapy
Cancer Vaccines
CAR-T Cell Therapy: Clinical Progress and Challenges
Next-Generation Cell and Gene Therapies in Oncology
Liquid Biopsy and Circulating Tumor DNA (ctDNA) Diagnostics
Companion Diagnostics
Artificial Intelligence and Machine Learning in Precision Oncology
Next-Generation Targeted Therapies: KRAS, HER2, BRAF, and NRAS
Overcoming Drug Resistance: Mechanisms and Solutions
Oncology Pipeline
Trends in Antibody–Drug Conjugates (ADCs)
Launch of Novel mAb Products for Cancer Therapy